-
Asian markets mixed as tech firms claw back some losses
-
Advanced economies must 'act now' to lower debt as bond yields spike: IMF
-
India shuts down iconic Delhi protest site after three decades
-
Deluge by design: Thai villages flooded to protect capital
-
Japan urges Russia for 'impartial treatment' of arrested journalist
-
Ivan Deforge, the French 'bison tamer' in Moscow
-
Lula, Bolsonaro ordered to call off attempts at online censorship
-
Indonesians on fire-ravaged island sue state for clean air
-
EU takes a page from Ireland's AI playbook
-
Trump, White House post video of UK man killed by tiger
-
Global deforestation slowed in 2025 but surged in Congo basin: study
-
Saudi employee arrested for allegedly bugging OpenAI office
-
Saudi says Houthi attacks sparked Aramco fire, wounded 4 in Riyadh
-
Atletico sink Man Utd as Viking deny Bayern in Champions League
-
Few buyers for starving cattle in El Nino parched El Salvador
-
Man United's Martinez blasts board's lack of investment
-
Bybit Expands Beyond Crypto as CEO Outlines Next Phase of Financial Platform
-
Meet A7 International, an Innovative Global Platform Designed to Reinvent the International Payments Market
-
Bayern held by Viking after 'super dumb' Olise red in Champions League
-
Shakhtar hope London move a reminder of Ukraine conflict
-
Why AI makes computer worms harder to stop
-
Tresoldi hat-trick fires Brugge past Inter Milan
-
US fines Bank of America $1.2 bn for anti-money laundering violations
-
Rams axe kicker Mevis after misses cost victory over Bills: reports
-
Bayern held by Viking after Olise sees red in Champions League
-
Yamal stays cool at boiling Galatasaray to lift Barcelona to victory
-
Atletico down Carrick's struggling Man United
-
Arsenal cruise past Lille into share of Champions League lead
-
Croatia trials full driverless robotaxi service
-
Trump ousts Greece ambassador over ethics scandal
-
US stocks dip ahead of inflation data as tech sell-off hits Asia
-
Reese Witherspoon, France's Mediawan to buy Hello Sunshine
-
No lights, no friends: Cuban youth grapple with loneliness
-
Bipartisan US senators urge Trump to scrap Russian diesel deal
-
Saudi coalition strikes Yemen oil sites after Houthi attacks
-
Ex-gang leader sentenced to minimum 40 years for Tupac murder
-
French economy minister denies country caught in debt 'snowball'
-
Cornell suspends frat parties after alleged gang rape
-
Judge extends halt to Trump's golf course tree-cutting
-
Man City deserve to keep titles, says PSG's Luis Enrique
-
Milan's Saelemaekers set for lenghty spell out after ankle surgery
-
Regulator 'will resign' if any political interference in Man City case
-
Nvidia says to invest in French medical website
-
Microsoft's Brad Smith calls for 'real and effective' AI safety standards
-
Real Madrid's Mourinho has 'trust' in referees despite complaints
-
Anthropic warns of AI 'worms' spreading across smart gadgets
-
Mendis, Shanaka star in Sri Lanka consolation T20I win
-
Big US banks report strong earnings and stay bullish on AI
-
Demonstrations backing France's protesting students gather strength
-
Iraola backs Barcola, Wirtz to come good for Liverpool
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
G.P.Martin--AT